<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611827</url>
  </required_header>
  <id_info>
    <org_study_id>2021-03-002</org_study_id>
    <nct_id>NCT05611827</nct_id>
  </id_info>
  <brief_title>Pharmacological Profile of Different Quercetin Formulations</brief_title>
  <official_title>Comparing the Pharmacological Profile of Different Quercetin Formulations in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Factors Group of Nutritional Companies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Factors Group of Nutritional Companies Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the pharmacokinetics of quercetin in healthy participants after&#xD;
      the administration of different formulations in a single- and multiple-dose phase. In the&#xD;
      single-dose study, plasma uptake (AUC0-24 and Cmax) of standard quercetin is compared with&#xD;
      that of LipoMicel®-a novel food-grade delivery form of quercetin. In the multiple dose study,&#xD;
      accumulating plasma concentrations of formulated quercetin are observed over 72hrs, after&#xD;
      repeated doses of LipoMicel treatments (AUC0-72).&#xD;
&#xD;
      At least ten healthy adults participate in an open-label, diet-controlled, crossover, plasma&#xD;
      uptake study. Participants receive three different doses (250 mg, 500 mg or 1000 mg) of&#xD;
      quercetin aglycone orally.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective of this study is to investigate the pharmacokinetic profile of formulated quercetin&#xD;
      (LipoMicel®), administered at three different doses, in healthy participants and compare it&#xD;
      with that of a standard formulation. The pharmacokinetics of the different quercetin&#xD;
      treatments are observed over 24hrs after a single orally administered dose of quercetin&#xD;
      (e.g., using AUC0-24 and Cmax). Furthermore, the accumulating plasma concentrations of&#xD;
      formulated quercetin are monitored over a 72hr period (e.g., using AUC0-72), following&#xD;
      multiple orally administered doses of LipoMicel treatments (250 mg-1000 mg) plus the&#xD;
      circulating metabolites of quercetin are determined in the human plasma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2022</start_date>
  <completion_date type="Actual">October 31, 2022</completion_date>
  <primary_completion_date type="Actual">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC: the area under the concentration-time curve</measure>
    <time_frame>0 (baseline; pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours</time_frame>
    <description>To evaluate the plasma uptake of orally ingested quercetin (aglycone) in a novel formulation (&quot;LipoMicel&quot;) in healthy adults by comparing the Area under the concentration-time curve (AUC) with that of standard/regular quercetin (aglycone).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: maximum plasma concentration</measure>
    <time_frame>0 (baseline; pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours</time_frame>
    <description>To evaluate the plasma uptake of orally ingested quercetin (aglycone) in a novel formulation (&quot;LipoMicel&quot;) in healthy adults by comparing the Peak Plasma Concentration (Cmax) with that of standard/regular quercetin (aglycone).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: the time point of maximum plasma concentration</measure>
    <time_frame>0 (baseline; pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours</time_frame>
    <description>To evaluate the plasma uptake of orally ingested quercetin (aglycone) in a novel formulation (&quot;LipoMicel&quot;) in healthy adults by comparing the time point of maximum plasma concentration (Tmax) with that of standard/regular quercetin (aglycone).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC: the area under the concentration-time curve (quercetin metabolites)</measure>
    <time_frame>0 (baseline; pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours</time_frame>
    <description>To determine the plasma concentrations of quercetin metabolites following the oral consumption of LipoMicel® 250 mg, over a period of 72hrs, by calculating AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: maximum plasma concentration (quercetin metabolites)</measure>
    <time_frame>0 (baseline; pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours</time_frame>
    <description>To determine the peak plasma concentrations of quercetin metabolites following the oral consumption of LipoMicel® 250 mg, over a period of 72hrs, by calculating Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: the time point of maximum plasma concentration (quercetin metabolites)</measure>
    <time_frame>0 (baseline; pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours</time_frame>
    <description>To determine the time point of maximum plasma concentration of quercetin metabolites following the oral consumption of LipoMicel® 250 mg, over a period of 72hrs, by calculating Tmax.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Quercetin LipoMicel (250 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant receives their treatment of Quercetin LipoMicel at a total dose of 250 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 250 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quercetin LipoMicel (500 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant receives their treatment of Quercetin LipoMicel at a total dose of 500 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 500 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quercetin LipoMicel (1000 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant receives their treatment of Quercetin LipoMicel at a total dose of 1000 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 1000 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular/standard Quercetin (500 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant receives their treatment of standard/raw Quercetin at a total dose of 500 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). A standardized lunch and dinner are served after 4h and 8h of product administration. Capillary whole blood samples are collected (after a 10hr overnight fast) at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin. A washout period of at least 7 days between each treatment will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Quercetin LipoMicel (250 mg)</intervention_name>
    <description>Quercetin LipoMicel® soft-gels. Total dose of 250 mg of quercetin</description>
    <arm_group_label>Quercetin LipoMicel (250 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Quercetin LipoMicel (500 mg)</intervention_name>
    <description>Quercetin LipoMicel® soft-gels. Total dose of 500 mg of quercetin</description>
    <arm_group_label>Quercetin LipoMicel (500 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Quercetin LipoMicel (1000 mg)</intervention_name>
    <description>Quercetin LipoMicel® soft-gels. Total dose of 1000 mg of quercetin</description>
    <arm_group_label>Quercetin LipoMicel (1000 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Regular/standard Quercetin (500 mg)</intervention_name>
    <description>Total dose of 500 mg of quercetin</description>
    <arm_group_label>Regular/standard Quercetin (500 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-65&#xD;
&#xD;
          -  healthy, good physical condition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy or breast-feeding&#xD;
&#xD;
          -  gastrointestinal conditions (acute or chronic)&#xD;
&#xD;
          -  liver disease (acute or chronic)&#xD;
&#xD;
          -  kidney disease (acute or chronic)&#xD;
&#xD;
          -  cardiovascular disease (acute or chronic)&#xD;
&#xD;
          -  hematological disease&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  allergy or intolerance to gluten&#xD;
&#xD;
          -  allergy or intolerance to quercetin&#xD;
&#xD;
          -  use of any form of nicotine or tobacco, CBD/THC&#xD;
&#xD;
          -  alcohol and substance abuse history&#xD;
&#xD;
          -  use of medications (e.g., anti-inflammatory)&#xD;
&#xD;
          -  use of quercetin supplements&#xD;
&#xD;
          -  participation in another investigational study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ISURA</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <zip>V3N4S9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 3, 2022</last_update_submitted>
  <last_update_submitted_qc>November 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

